---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-022312"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T03:05:03.595154+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics amends Hayfin credit agreement, cuts rate by 1%, extends $25M delayed draw loan

## Summary
- Interest rate reduced 1% to SOFR + 8.50%; up to 2.50% interest may be paid in kind.
- New 50% waiver of prepayment fee on acquisition or strategic transactions within 24 months.
- Delayed draw term loan of $25M extended from June 30, 2023 to December 31, 2023.
- Issued warrants for 2,391,244 shares at $3.2619 per share, expiring May 1, 2030.
- Total debt level unchanged; company cites strengthened financial outlook.

## SEC filing metadata
- accession: 0001140361-23-022312
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036123022312/0001140361-23-022312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036123022312/brhc20052223_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-022312
- JSON: https://secwatch.observer/filing/0001140361-23-022312.json
- Plain text: https://secwatch.observer/filing/0001140361-23-022312.txt

## Key facts
- Material Agreements
  ADMA BIOLOGICS, INC. amended Amendment No. 2 with Hayfin Services LLP and the lenders identified therein (effective 2023-05-01).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Hayfin Services LLP and the lenders identified therein
  - Effective: 2023-05-01
  source text: On May 1, 2023 (the “Amendment Closing Date”), ADMA Biologics, Inc. (the “Company”) entered into Amendment No. 2 (the “Amendment”) to the Credit Agreement and Guaranty, dated as of March 23, 2022, as previously amended by that certain Amendment No. 1 to the Credit Agreement and Guaranty, dated as of March 22, 2023 (the “Hayfin Credit Agreement”), with Hayfin Services LLP and the lenders identified therein (collectively, “Hayfin”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036123022312/0001140361-23-022312-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.